About 300 reports

TABLE ## LUNG CANCER SURVIVAL RATE FOR DIFFERENT STAGES, BY TYPE OF LUNG CANCER, 2021

  • Lung Cancer
  • World
  • United States
  • North America
  • Europe
  • Asia
  • Cancer Incidence
  • Health Expenditure

Abstract: - Global Lung Cancer Therapeutics Market to Reach $44.4 Billion by 2027 - Amid the COVID-19 crisis, the global market for Lung Cancer Therapeutics estimated at US$20.4 Billion in the year 2020, is projected to reach a revised size of US$44.4 Billion by 2027, growing at aCAGR of 11.7% over the period 2020-2027....

  • Lung Cancer
  • World
  • China
  • United States

Abstract: - Global Lung Cancer Surgery Market to Reach $37.4 Billion by 2027 - Amid the COVID-19 crisis, the global market for Lung Cancer Surgery estimated at US$25.5 Billion in the year 2020, is projected to reach a revised size of US$37.4 Billion by 2027, growing at aCAGR of 5.6% over the period 2020-2027. Thoracotomy,...

  • Lung Cancer
  • World
  • United States
  • China

“Small Cell Lung Cancer – Pipeline Insight, 2021,” report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route...

  • Lung Cancer
  • World

“Extensive Stage Small Cell Lung Cancer - Pipeline Insight, 2021,” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Extensive Stage Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment...

  • Lung Cancer
  • World
  • Life Expectancy

Small Cell Lung Cancer

  • Lung Cancer
  • Epidemiology
  • Biomarker
  • World
  • Smoking Prevalence
  • Cancer Incidence

Non-Small Cell Lung Cancer:

  • Lung Cancer
  • World
  • Smoking Prevalence
  • Cancer Incidence

Major players in the lung cancer drugs market are Bristol-Myers Squibb Company, Merck & Co., F. Hoffmann-La Roche Ltd, Novartis AG, and Pfizer Inc. The global lung cancer drugs market is expected to grow from $8.06 billion in 2020 to $8.67 billion in 2021 at a compound annual growth rate (CAGR) of 7.6%. The growth is mainly due to the...

  • Lung Cancer
  • World
  • Biologics Penetration Rate
  • Mortality Rate

Lung Cancer Surgery Market Report Overview Lung Cancer Surgery market size outlook report provides comprehensive coverage of market landscape including strategic growth areas, unique insights, and major trends across Lung Cancer Surgery market types and applications. It is a focused study on Lung Cancer Surgery market space including global...

  • Lung Cancer
  • World
  • Health Provider Density

Lung Cancer Therapeutics Market Report Overview Lung Cancer Therapeutics market size outlook report provides comprehensive coverage of market landscape including strategic growth areas, unique insights, and major trends across Lung Cancer Therapeutics market types and applications. It is a focused study on Lung Cancer Therapeutics market...

  • Lung Cancer
  • World
  • Health Provider Density

Small-Cell Lung Cancer - Pipeline Review, H1 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Small-Cell Lung Cancer - Pipeline Review, H1 2020, provides an overview of the Small-Cell Lung Cancer (Oncology) pipeline landscape. Small cell lung cancer (SCLC)...

  • Lung Cancer
  • World

“Non-Small Cell Lung Cancer (NSCLC) – Pipeline Insight, 2020,” report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in Non-Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type,...

  • Lung Cancer
  • World

Abstract: - Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market to Reach $44.6 Billion by 2027 - Amid the COVID-19 crisis, the global market for Non-Small Cell Lung Cancer (NSCLC) Therapeutics estimated at US$20 Billion in the year 2020, is projected to reach a revised size of US$44.6 Billion by 2027, growing...

  • Lung Cancer
  • Therapy
  • World
  • China
  • United States

Non-Small Cell Lung Cancer - Pipeline Review, H1 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Non-Small Cell Lung Cancer - Pipeline Review, H1 2020, provides an overview of the Non-Small Cell Lung Cancer (Oncology) pipeline landscape. Non-small cell lung...

  • Lung Cancer
  • World

“EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) – Pipeline Insight, 2020,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in EGFR Non-Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment...

  • Lung Cancer
  • World

“ALK-positive Non-Small Cell Lung Cancer (ALK+ NSCLC) – Pipeline Insight, 2020,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in ALK-positive Non-Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics...

  • Lung Cancer
  • World
  • China

“PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) – Pipeline Insight, 2020,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in PD-1 Non-Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment...

  • Lung Cancer
  • World

Small-Cell Lung Cancer - Pipeline Review, H2 2019 Summary The latest Pharmaceutical and Healthcare disease pipeline guide Small-Cell Lung Cancer - Pipeline Review, H2 2019, provides an overview of the Small-Cell Lung Cancer (Oncology) pipeline landscape. Small cell lung cancer (SCLC)...

  • Lung Cancer
  • World

‘Anaplastic lymphoma kinase-Non Small Cell Lung Cancer (ALK-NSCLC)- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted ALK NSCLCepidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. Anaplastic...

  • Lung Cancer
  • Germany
  • Spain
  • Japan
  • United States
  • France
  • Italy
  • United Kingdom

A recent market study published on the lung cancer surgery market includes global industry analysis for 2014-2018 & opportunity assessment for 2019 - 2029, and delivers a comprehensive assessment of the most important market dynamics. After conducting a thorough research on the historical as well as current growth parameters of the lung cancer...

  • Lung Cancer
  • World
  • South Asia

‘BRAF Mutated Non-small Cell Lung Cancer (NSCLC)- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted BRAF Mutated NSCLC epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. BRAF Mutated NSCLC...

  • Lung Cancer
  • France
  • Germany
  • United Kingdom
  • Spain
  • Japan
  • United States
  • Italy

‘Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC) - Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted PD-L1 NSCLC epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. PD-L1...

  • Lung Cancer
  • Germany
  • Spain
  • Japan
  • United States
  • France
  • Italy
  • United Kingdom

‘Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC)-Market Insights, Epidemiology and Market Forecast—2030’ report delivers an in-depth understanding of the ALK NSCLC, historical and forecasted epidemiology as well as the ALK NSCLC market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and...

  • Lung Cancer
  • United States
  • Japan
  • Germany
  • Health Expenditure
  • Drug Approval

"Non-Small Cell Lung Cancer - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020" report offers comprehensive insights on marketed and Phase III products for Non-Small Cell Lung Cancer. The marketed products information covers their product details, patents (US & EU), historical and forecasted sales till 2023. It further...

  • Lung Cancer
  • World
  • United States
  • Health Expenditure

‘Cellular-mesenchymal Epithelial Transition Factor (C-Met) Mutated Non-small Cell Lung Cancer (NSCLC)- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted c-Met Mutated NSCLC epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom),...

  • Lung Cancer
  • France
  • Japan
  • Germany
  • United Kingdom
  • Spain
  • United States
  • Italy

‘BRAF Mutated Non-small Cell Lung Cancer (NSCLC) -Market Insights, Epidemiology and Market Forecast—2030’ report delivers an in-depth understanding of the BRAF Mutated NSCLC, historical and forecasted epidemiology as well as the BRAF Mutated NSCLC market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),...

  • Lung Cancer
  • Therapy
  • United States
  • Japan
  • France
  • Germany
  • United Kingdom
  • Health Expenditure

Global Lung Cancer Liquid Biopsy Market 2020-2024 The analyst has been monitoring the lung cancer liquid biopsy market and it is poised to grow by $ 292.89 mn during 2020-2024, progressing at a CAGR of 16% during the forecast period. Our reports on the lung cancer liquid biopsy market provide a holistic analysis, market...

  • Lung Cancer
  • Genetic Testing
  • World

Lung Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2020 Summary Medical Devices sector report, “Lung Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Lung Cancer Diagnostic Tests pipeline products with comparative...

  • Lung Cancer

Squamous Non-Small Cell Lung Cancer (Oncology) - Drugs in Development, 2021 Summary Squamous Non-Small Cell Lung Cancer (Oncology) - Drugs in Development, 2021 provides an overview of the Squamous Non-Small Cell Lung Cancer pipeline landscape. The report provides comprehensive information...

  • Lung Cancer
  • World

‘Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC)-Market Insights, Epidemiology and Market Forecast—2030’ report delivers an in-depth understanding of the PD-L1 NSCLC ,historical and forecasted epidemiology as well as the PD-L1 NSCLC market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United...

  • Lung Cancer
  • United States
  • Japan
  • Germany
  • United Kingdom
  • Spain
  • France
  • Italy
  • Health Expenditure
  • Use Of Prescription Drugs